For the multi-site open-label extension study of MDMA-assisted psychotherapy for PTSD (MAPPUSX) sponsored by MAPS, Numinus will manage two new clinics in Montreal and Vancouver.
The largest psilocybin therapy clinical trial ever conducted, investigating psilocybin for treatment-resistant depression (TRD), has achieved its primary endpoint.
Kicking off the Microdose Wonderland conference in Miami, Cybin Inc announced it will be moving its psilocybin analogue – CYB003 – into clinical trials.
The findings from a Phase II A/B study, which is the world’s first study on ketamine-assisted psychotherapy for alcohol use disorder, will be published in the...
Braxia Scientific Corp.
Biotechnology company Beckley Psytech has welcomed neuroscience expert Dr Frank Wiegand to its team as Chief Medical Officer.
Researchers have discovered changes in the brain associated with LSD which they say could help gain insights into how the brain generates behaviour.
Biotech company, Mind Medicine Inc, is expanding its drug development pipeline with the launch of a programme to develop R(-)-MDMA for the treatment of social anxiety...
New data from the Aquilino Cancer Center Study has shown the safety and feasibility of psilocybin therapy for the treatment of depression in cancer patients.
A novel MDMA-like chemical series have been identified with drug-like properties which will be developed to treat addiction.
New data has shown that Amanita Muscaria extract (AME-1) has a potential new functional property – inhibiting human mast cell activation – which could hold promise...
A clinical trial investigating the safety and tolerability of a novel formulation of 5-MeO-DMT in psychedelic-naive subjects has dosed its first cohort of volunteers.